Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.

about

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

P2860

Q58765630-8E87AC98-4961-47F8-B131-37F37BF729C3

P2860

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.

Item

http://www.wikidata.org/entity/Q46638388

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@en

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@nl

type

Item

label

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@en

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@nl

prefLabel

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@en

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@nl

P1476

Economic Impact of Mirabegron ...... Overactive Bladder in the UK.

@en

P2093

Adrian Wagg

http://www.w3.org/2001/XMLSchema#string

Charles McCrea

http://www.w3.org/2001/XMLSchema#string

Francis Fatoye

http://www.w3.org/2001/XMLSchema#string

Jameel Nazir

http://www.w3.org/2001/XMLSchema#string

Malin Berling

http://www.w3.org/2001/XMLSchema#string

Sally Bowditch

http://www.w3.org/2001/XMLSchema#string

Zalmai Hakimi

http://www.w3.org/2001/XMLSchema#string

P2860

Mirabegron: a review of recent data and its prospects in the management of overactive bladder

Persistence and compliance with medication management in the treatment of overactive bladder

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Comorbidities associated with overactive bladder.

Overactive bladder significantly affects quality of life.

Prevalence and burden of overactive bladder in the United States.

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

P2888

s41669-017-0011-x

P304

25-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S41669-017-0011-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29442303

http://www.w3.org/2001/XMLSchema#string

P932

5689035

http://www.w3.org/2001/XMLSchema#string

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.

about

P2860

P2860

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932